NYSE:AGNAllergan Stock Price, Forecast & News

Allergan's stock was trading at $185.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AGN stock has increased by 4.1% and is now trading at $193.02. View which stocks have been most impacted by Coronavirus.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 12 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Allergan.

Allergan is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Allergan.

Allergan plc (NYSE:AGN) posted its earnings results on Monday, February, 10th. The company reported $5.22 EPS for the quarter, topping the consensus estimate of $4.57 by $0.65. The company earned $4.35 billion during the quarter, compared to analyst estimates of $4.09 billion. Allergan had a positive return on equity of 8.46% and a negative net margin of 15.44%. The business's quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $4.29 earnings per share. View Allergan's earnings history.

Allergan announced a quarterly dividend on Wednesday, March 18th. Investors of record on Thursday, April 16th will be given a dividend of $0.74 per share on Monday, June 15th. This represents a $2.96 annualized dividend and a dividend yield of 1.53%. The ex-dividend date is Wednesday, April 15th. View Allergan's dividend history.

Allergan announced that its Board of Directors has approved a share repurchase program on Tuesday, January 29th 2019, which permits the company to buyback $2,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to repurchase up to 4.1% of its stock through open market purchases. Stock buyback programs are generally a sign that the company's management believes its shares are undervalued.

13 brokerages have issued twelve-month target prices for Allergan's stock. Their forecasts range from $165.00 to $203.00. On average, they anticipate Allergan's stock price to reach $186.71 in the next year. This suggests that the stock has a possible downside of 3.3%. View analysts' price targets for Allergan.

News stories about AGN stock have been trending very positive recently, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Allergan earned a news impact score of 3.5 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutAllergan.

Some companies that are related to Allergan include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), United Rentals (URI) and Transocean (RIG).

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Allergan's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.42%), State Street Corp (4.15%), Longview Partners Guernsey LTD (1.52%), Clearbridge Investments LLC (1.24%), JPMorgan Chase & Co. (1.12%) and Morgan Stanley (0.84%). Company insiders that own Allergan stock include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi and Matthew M Walsh. View institutional ownership trends for Allergan.

AGN stock was sold by a variety of institutional investors in the last quarter, including Longview Partners Guernsey LTD, Nuveen Asset Management LLC, Clearbridge Investments LLC, State Street Corp, Segantii Capital Management Ltd, Scharf Investments LLC, Canyon Capital Advisors LLC, and Mackenzie Financial Corp. View insider buying and selling activity for Allergan.

AGN stock was acquired by a variety of institutional investors in the last quarter, including Syquant Capital Sas, JPMorgan Chase & Co., ING Groep NV, BlackRock Inc., Water Island Capital LLC, Maso Capital Partners Ltd, Glazer Capital LLC, and Swiss National Bank. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, and Matthew M Walsh. View insider buying and selling activity for Allergan.

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AGN stock can currently be purchased for approximately $193.02.

Allergan has a market capitalization of $63.50 billion and generates $16.09 billion in revenue each year. The company earns $-5,271,000,000.00 in net income (profit) each year or $17.64 on an earnings per share basis. Allergan employs 17,400 workers across the globe.

The official website for Allergan is www.allergan.com.

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]